BD Clarkson

4.2k total citations · 2 hit papers
57 papers, 3.2k citations indexed

About

BD Clarkson is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, BD Clarkson has authored 57 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 20 papers in Genetics and 14 papers in Pathology and Forensic Medicine. Recurrent topics in BD Clarkson's work include Acute Myeloid Leukemia Research (21 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Lymphoma Diagnosis and Treatment (14 papers). BD Clarkson is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Lymphoma Diagnosis and Treatment (14 papers). BD Clarkson collaborates with scholars based in United States, Germany and Japan. BD Clarkson's co-authors include JE Sokal, Francisco Cervantes, S Tura, Michele Baccarani, GA Gomez, C. Y. Tso, Cox Eb, Benjamín Koziner, RS Chaganti and TS Gee and has published in prestigious journals such as Blood, PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).

In The Last Decade

BD Clarkson

56 papers receiving 3.0k citations

Hit Papers

Prognostic discrimination in "good-risk" chronic granuloc... 1984 2026 1998 2012 1984 1984 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
BD Clarkson United States 25 2.2k 1.7k 764 649 632 57 3.2k
Nicoletta Testoni Italy 35 3.7k 1.7× 1.9k 1.1× 1.0k 1.3× 347 0.5× 676 1.1× 187 4.4k
John Nicoll United States 18 1.9k 0.8× 1.4k 0.8× 919 1.2× 338 0.5× 294 0.5× 30 3.2k
Mario Sessarego Italy 28 1.8k 0.8× 882 0.5× 242 0.3× 189 0.3× 465 0.7× 122 2.3k
Marilina Amabile Italy 28 2.5k 1.1× 1.6k 0.9× 1.1k 1.4× 289 0.4× 375 0.6× 80 2.9k
MJ Keating United States 30 1.2k 0.6× 1.7k 1.0× 150 0.2× 983 1.5× 719 1.1× 54 3.1k
JW Vardiman United States 30 2.2k 1.0× 1.1k 0.6× 118 0.2× 541 0.8× 857 1.4× 52 3.3k
Laurence Legros France 30 3.6k 1.6× 2.7k 1.6× 1.5k 2.0× 314 0.5× 403 0.6× 126 4.1k
AB Deisseroth United States 33 2.0k 0.9× 683 0.4× 159 0.2× 309 0.5× 405 0.6× 69 3.0k
Jean‐Louis Michaux Belgium 28 1.5k 0.7× 786 0.5× 126 0.2× 520 0.8× 341 0.5× 71 2.5k
Barbara Waßmann Germany 23 2.3k 1.0× 1.1k 0.6× 925 1.2× 150 0.2× 1.2k 1.9× 48 2.9k

Countries citing papers authored by BD Clarkson

Since Specialization
Citations

This map shows the geographic impact of BD Clarkson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by BD Clarkson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites BD Clarkson more than expected).

Fields of papers citing papers by BD Clarkson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by BD Clarkson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by BD Clarkson. The network helps show where BD Clarkson may publish in the future.

Co-authorship network of co-authors of BD Clarkson

This figure shows the co-authorship network connecting the top 25 collaborators of BD Clarkson. A scholar is included among the top collaborators of BD Clarkson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with BD Clarkson. BD Clarkson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lemoli, Roberto M., Cristina Gasparetto, DA Scheinberg, et al.. (1991). Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood. 77(8). 1829–1836. 2 indexed citations
2.
Lemoli, Roberto M., SC Gulati, A Strife, et al.. (1991). Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.. PubMed. 5(5). 386–91. 30 indexed citations
3.
Lemoli, Roberto M., Cristina Gasparetto, DA Scheinberg, et al.. (1991). Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood. 77(8). 1829–1836. 42 indexed citations
4.
Shimazaki, Chihiro, Tohru Inaba, Naoto Fujita, et al.. (1990). Purging of myeloma cells from bone marrow using monoclonal antibodies and magnetic immunobeads in combination with 4-hydroperoxycyclophosphamide.. PubMed. 333. 311–9. 2 indexed citations
5.
Cunningham, Isabel, et al.. (1989). Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 73(5). 1116–1122. 155 indexed citations
6.
Cunningham, Isabel, et al.. (1989). Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 73(5). 1116–1122. 21 indexed citations
7.
Sokal, JE, GA Gomez, Michele Baccarani, et al.. (1988). Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 72(1). 294–298. 82 indexed citations
8.
Sokal, JE, GA Gomez, Michele Baccarani, et al.. (1988). Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 72(1). 294–298. 91 indexed citations
10.
Mertelsmann, R, Cora N. Sternberg, R.J. O’Reilly, et al.. (1984). Treatment of immunodeficiency with interleukin-2: initial exploration.. PubMed. 3(5). 483–90. 21 indexed citations
11.
12.
13.
Cw, Young, et al.. (1980). Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing. Blood. 55(5). 831–834. 65 indexed citations
14.
Singer, Jack W., Arlin Za, Vesna Najfeld, et al.. (1980). Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia (CML) following a chemotherapy-induced loss of the Ph1 chromosome. Blood. 56(3). 356–360. 61 indexed citations
15.
Cunningham, Isabel, et al.. (1978). The L-5 protocol: intensive treatment for patients with chronic myeloid leukemia.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 57(3). 289–93. 1 indexed citations
16.
Chou, Ting‐Chao, et al.. (1977). Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.. PubMed. 37(10). 3561–70. 94 indexed citations
17.
Clarkson, BD, et al.. (1977). Cyclophosphamide L2 protocol: a combination chemotherapeutic regimen for advanced non-hodgkin's lymphoma.. PubMed. 61(1). 7–16. 10 indexed citations
18.
Cw, Young, et al.. (1976). Eight-drug combination chemotherapy (MOPP and ABDV) and local radiotherapy for advanced Hodgkin's Disease.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 60(9). 1217–23. 20 indexed citations
19.
Clarkson, BD. (1969). Review of recent studies of cellular proliferation in acute leukemia.. PubMed. 30. 81–120. 53 indexed citations
20.
Hf, Oettgen, Old Lj, Boyse Ea, et al.. (1967). Inhibition of leukemias in man by L-asparaginase.. PubMed. 27(12). 2619–31. 223 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026